XML 44 R35.htm IDEA: XBRL DOCUMENT
v3.26.1

Collaboration and License Agreements - Amgen, Inc - Additional Information (Details) - USD ($) $ in Thousands |  |  | 1 Months Ended | 6 Months Ended
--- | --- | --- | --- | ---
Mar. 19, 2026 | Sep. 29, 2017 | May 31, 2025 | Jun. 30, 2026 | Jun. 30, 2025
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Common stock, value of shares issued in connection with agreement | $ 234,200 |  | $ 93,400 | $ 228,407 | $ 93,373
Collaboration and License Agreement | Amgen Inc |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Upfront payment received |  | $ 40,000 |  |  |
Common stock, value of shares issued in connection with agreement |  | 20,000 |  |  |
Collaboration and License Agreement | Amgen Inc | Maximum |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |
Contingent payments payable |  | $ 203,000 |  |  |

X
- Definition Contingent payments payable upon achieving development regulatory and commercial milestones. + References No definition available. + Details
Name: | ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |